Clinical trialNCT07644559RecruitingPhase 2Interventional

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

SponsorVerastem, Inc.Enrollment180G12D Mutated KRASPancreatic Ductal Adenocarcinoma (PDAC)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Icon Kurralta Park
Kurralta Park, South Australia, Australia
Carolyn Bampton, MD
Recruiting
Icon Cancer Centre
South Brisbane, Australia
Jermaine Coward, MD
Recruiting

United States

Cedars-Sinai Medical Center
Los Angeles, California, United States
Arsen Osipov, MD
Recruiting
Start- Los Angeles
Los Angeles, California, United States
Navid Hafez, MD
Recruiting
Valkyrie Clinical Trials
Los Angeles, California, United States
David Berz, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Dae-Won Kim, MD
Recruiting
Johns Hopkins University
Baltimore, Maryland, United States
Mari Nakazawa, MD
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Kimberly Perez, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Harshabad Singh, MD
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Vaibhav Sahai, MD
Recruiting
Start Midwest
Grand Rapids, Michigan, United States
Sreenivasa Chandana, MD
Recruiting
Washington University
St Louis, Missouri, United States
Kian-Huat Lim, MD
Recruiting
Start New Jersey
East Brunswick, New Jersey, United States
Bruno Fang, MD
Recruiting
Nyu-Manhattan
New York, New York, United States
Kristen Spencer, MD
Recruiting
University of North Carolina
Chapel Hill, North Carolina, United States
Ashwin Somasundaram, MD
Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Meredith Pelster, MD
Recruiting
Start Dallas
Fort Worth, Texas, United States
Salwan Almutar, MD
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Shubham Pant, MD
Recruiting
Start- San Antonio
San Antonio, Texas, United States
Drew Rasco, MD
Recruiting
Start- Mountain Region
West Valley City, Utah, United States
William McKean, MD
Recruiting
Uva Health
Charlottesville, Virginia, United States
Matthew Reilley, MD
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Alexander Spira, MD
Recruiting
Virginia Mason
Seattle, Washington, United States
Vincent Picozzi, MD
Recruiting
Uw Health
Madison, Wisconsin, United States
Noelle LoConte, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

VS-7375 →Cetuximab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Jun 2026
Primary completion: 30 Jun 2027
Completion: 31 Dec 2028
Last update posted: 17 Aug 2026
Registered enrollment: 180
Registry id: NCT07644559

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.